Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53BP1 | Q12888 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21365274 | 0.85 | KDM4C (0.46) | KDM4CEPHX1NPC1RAB9AMAPT | |
| SCHEMBL21449037 | 0.83 | EPHX1 (0.41) | KDM4CEPHX1NPC1RAB9AMAPT | |
| SCHEMBL22386549 | 0.82 | KDM4C (0.43) | KDM4CEPHX1NPC1RAB9AMAPT | |
| SCHEMBL20026571 | 0.82 | KDM4C (0.50) | KDM4CEPHX1NPC1RAB9AMAPT | |
| SCHEMBL20029310 | 0.79 | KDM4C (0.74) | KDM4CEPHX1NPC1RAB9AMAPT | |
| SCHEMBL20026476 | 0.78 | KDM4C (0.50) | KDM4CEPHX1NPC1RAB9AMAPT | |
| SCHEMBL20462313 | 0.78 | KDM4C (0.60) | KDM4CEPHX1 | |
| SCHEMBL26309035 | 0.77 | KEAP1 (0.39) | KDM4CEPHX1NPC1RAB9AMAPT | |
| SCHEMBL7751127 | 0.76 | KDM4E (0.50) | RAB9AMAPTTP53BP1KDM4EMAPK1 | |
| SCHEMBL19171338 | 0.75 | NPC1 (0.57) | KDM4CEPHX1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360487-A1 | PTH PRODRUGS | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360487-A1 | PTH PRODRUGS | PTH1R, PTMS, PHPT1 | KDM4C 2681/4885EPHX1 878/4885NPC1 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.